Amicus Therapeutics (FOLD) Tops Q3 EPS by 3c, Beats on Revenue

Amicus Therapeutics (NASDAQ: FOLD) reported Q3 EPS of $0.06, $0.03 better than the analyst estimate of $0.03. Revenue for the quarter came in at $169.06 million versus the consensus estimate of $165.44 million.

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Independence Realty Trust (IRT) files mixed shelf
• Venu Holding enters $250 million at-the-market stock offering agreement